Effectiveness and Safety of Omalizumab in Children With Allergic Asthma.

Part of paid clinical trials in East Hanover, New Jersey.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT05424523
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
6 Years - 11 Years
Healthy Volunteers
Not accepted

Interventions

  • Omalizumab — DRUG
    Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab

Study Details

The study was the non-interventional, retrospective study aimed to assess the effectiveness and safety of omalizumab in children with allergic asthma in China, and described patient profiles and treatment patterns of omalizumab in real-world practice.

Key Dates

Start date
Feb 25, 2021
Status verified
Jun 2022
Primary completion
Jun 28, 2021
Completion
Jun 28, 2021

Study Design

Enrollment
200 participants (actual)

Arms

  • Arm: Omalizumab
    Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab

Primary Outcome Measure

Proportion of patients who responded to omalizumab [ Time Frame: After 4-6 months of treatment (Between July 6, 2018 to September 30, 2020) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Novartis Investigative SiteEast HanoverNew Jersey07936-1080-

Find similar trials in East Hanover, NJ

By condition
Asthma
By specialty
PulmonologyLung disease
By research site
Novartis Investigative Site· East Hanover, NJ

Related Studies